Literature DB >> 29485130

The rs626283 Variant in the MBOAT7 Gene is Associated with Insulin Resistance and Fatty Liver in Caucasian Obese Youth.

Giuseppina R Umano1,2, Sonia Caprio1, Anna Di Sessa1,2, Naga Chalasani3, Daniel J Dykas4, Bridget Pierpont1, Allen E Bale4, Nicola Santoro1.   

Abstract

OBJECTIVES: Non alcoholic fatty liver disease (NAFLD) is a leading cause of liver damage in childhood, its occurrence is influenced by genetic and environmental factors. Recently, the rs626283 polymorphism in the MBOAT7 gene has been found to be associated with alcoholic liver disease and NAFLD in adults.
METHODS: In a multiethnic cohort of obese children and adolescents we genotyped the rs626283 polymorphism in the MBOAT7 gene, evaluated insulin sensitivity by an oral glucose tolerance test, and measured the intra-hepatic fat content (HFF%) by magnetic resonance imaging.
RESULTS: In Caucasian youth, the minor allele (C) was associated with HFF% in (P=0.003), fasting insulin (P=0.03), area under the curve of glucose (P=0.03), and lower degree of whole-body insulin sensitivity (P=0.01) independent of age, gender, and body mass index z-score. A partial correlation showed that the association between the rs626283 variant and insulin resistance was driven by the presence of hepatic steatosis (P=0.009). However, there was no association between the rs626283 and hepatic steatosis among Hispanic and African American children and youth. The association between the rs626283 in the MBOAT7 gene among Caucasians was independent of the PNPLA3 rs738409, GCKR 1260326, and TM6SF2 rs58542926 (P=0.01). The four polymorphisms combined explained~19% of the HFF% in Caucasian obese children and adolescents.
CONCLUSIONS: The rs626283 variant in the MBOAT7 gene is associated with NAFLD and may affect glucose metabolism by modulating intra-hepatic fat content in Caucasian obese children and adolescents.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29485130     DOI: 10.1038/ajg.2018.1

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  31 in total

1.  I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.

Authors:  Luca Valenti; Anna Alisi; Enrico Galmozzi; Andrea Bartuli; Benedetta Del Menico; Arianna Alterio; Paola Dongiovanni; Silvia Fargion; Valerio Nobili
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

2.  Hepatic De Novo Lipogenesis in Obese Youth Is Modulated by a Common Variant in the GCKR Gene.

Authors:  Nicola Santoro; Sonia Caprio; Bridget Pierpont; Michelle Van Name; Mary Savoye; Elizabeth J Parks
Journal:  J Clin Endocrinol Metab       Date:  2015-06-04       Impact factor: 5.958

3.  Association of MBOAT7 gene variant with plasma ALT levels in children: the PANIC study.

Authors:  Anna Viitasalo; Aino-Maija Eloranta; Mustafa Atalay; Stefano Romeo; Jussi Pihlajamäki; Timo A Lakka
Journal:  Pediatr Res       Date:  2016-07-13       Impact factor: 3.756

4.  The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans.

Authors:  Panu K Luukkonen; You Zhou; Tuulia Hyötyläinen; Marja Leivonen; Johanna Arola; Marju Orho-Melander; Matej Orešič; Hannele Yki-Järvinen
Journal:  J Hepatol       Date:  2016-08-09       Impact factor: 25.083

5.  Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents.

Authors:  Nicola Santoro; Clarence K Zhang; Hongyu Zhao; Andrew J Pakstis; Grace Kim; Romy Kursawe; Daniel J Dykas; Allen E Bale; Cosimo Giannini; Bridget Pierpont; Melissa M Shaw; Leif Groop; Sonia Caprio
Journal:  Hepatology       Date:  2011-12-18       Impact factor: 17.425

6.  Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study.

Authors:  Marcin Krawczyk; Monika Rau; Jörn M Schattenberg; Heike Bantel; Anita Pathil; Münevver Demir; Johannes Kluwe; Tobias Boettler; Frank Lammert; Andreas Geier
Journal:  J Lipid Res       Date:  2016-11-11       Impact factor: 5.922

Review 7.  Pediatric fatty liver disease: role of ethnicity and genetics.

Authors:  Pierluigi Marzuillo; Emanuele Miraglia del Giudice; Nicola Santoro
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

8.  Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study.

Authors:  Martina Goffredo; Sonia Caprio; Ariel E Feldstein; Ebe D'Adamo; Melissa M Shaw; Bridget Pierpont; Mary Savoye; Hongyu Zhao; Allen E Bale; Nicola Santoro
Journal:  Hepatology       Date:  2015-11-16       Impact factor: 17.425

9.  The association between hepatic fat content and liver injury in obese children and adolescents: effects of ethnicity, insulin resistance, and common gene variants.

Authors:  Nicola Santoro; Ariel E Feldstein; Erik Enoksson; Bridget Pierpont; Romy Kursawe; Grace Kim; Sonia Caprio
Journal:  Diabetes Care       Date:  2012-12-28       Impact factor: 19.112

10.  The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver.

Authors:  Nicola L Beer; Nicholas D Tribble; Laura J McCulloch; Charlotta Roos; Paul R V Johnson; Marju Orho-Melander; Anna L Gloyn
Journal:  Hum Mol Genet       Date:  2009-07-30       Impact factor: 6.150

View more
  14 in total

Review 1.  MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD.

Authors:  Marica Meroni; Miriam Longo; Anna L Fracanzani; Paola Dongiovanni
Journal:  EBioMedicine       Date:  2020-07-03       Impact factor: 8.143

Review 2.  The Liver in Children With Metabolic Syndrome.

Authors:  Ebe D'Adamo; Valeria Castorani; Valerio Nobili
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-02       Impact factor: 5.555

3.  Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease.

Authors:  Jing Zeng; Rui-Xu Yang; Chao Sun; Qin Pan; Rui-Nan Zhang; Guang-Yu Chen; Ying Hu; Jian-Gao Fan
Journal:  World J Gastroenterol       Date:  2020-04-21       Impact factor: 5.742

Review 4.  PNPLA3-A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease.

Authors:  Xiaocheng Charlie Dong
Journal:  Front Med (Lausanne)       Date:  2019-12-17

5.  LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover.

Authors:  Yuki Tanaka; Yuta Shimanaka; Andrea Caddeo; Takuya Kubo; Yanli Mao; Tetsuya Kubota; Naoto Kubota; Toshimasa Yamauchi; Rosellina Margherita Mancina; Guido Baselli; Panu Luukkonen; Jussi Pihlajamäki; Hannele Yki-Järvinen; Luca Valenti; Hiroyuki Arai; Stefano Romeo; Nozomu Kono
Journal:  Gut       Date:  2020-04-06       Impact factor: 23.059

Review 6.  New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease.

Authors:  Yu-Cheng Lin; Chi-Chien Wu; Yen-Hsuan Ni
Journal:  Front Pediatr       Date:  2020-12-09       Impact factor: 3.418

7.  The PNPLA3 rs738409 Variant but not MBOAT7 rs641738 is a Risk Factor for Nonalcoholic Fatty Liver Disease in Obese U.S. Children of Hispanic Ethnicity.

Authors:  Sana Mansoor; Anshu Maheshwari; Matthew Di Guglielmo; Katryn Furuya; Makala Wang; Erin Crowgey; Zarela Molle-Rios; Zhaoping He
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2021-09-08

Review 8.  Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From "two hit theory" to "multiple hit model".

Authors:  Yan-Lan Fang; Hong Chen; Chun-Lin Wang; Li Liang
Journal:  World J Gastroenterol       Date:  2018-07-21       Impact factor: 5.742

Review 9.  The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease.

Authors:  Hideki Fujii; Norifumi Kawada
Journal:  Int J Mol Sci       Date:  2020-05-29       Impact factor: 5.923

10.  rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis.

Authors:  Kevin Teo; Kushala W M Abeysekera; Leon Adams; Elmar Aigner; Quentin M Anstee; Jesus M Banales; Rajarshi Banerjee; Priyadarshi Basu; Thomas Berg; Pallav Bhatnagar; Stephan Buch; Ali Canbay; Sonia Caprio; Ankita Chatterjee; Yii-Der Ida Chen; Abhijit Chowdhury; Ann K Daly; Christian Datz; Dana de Gracia Hahn; Johanna K DiStefano; Jiawen Dong; Amedine Duret; Connor Emdin; Madison Fairey; Glenn S Gerhard; Xiuqing Guo; Jochen Hampe; Matthew Hickman; Lena Heintz; Christian Hudert; Harriet Hunter; Matt Kelly; Julia Kozlitina; Marcin Krawczyk; Frank Lammert; Claudia Langenberg; Joel Lavine; Lin Li; Hong Kai Lim; Rohit Loomba; Panu K Luukkonen; Phillip E Melton; Trevor A Mori; Nicholette D Palmer; Constantinos A Parisinos; Sreekumar G Pillai; Faiza Qayyum; Matthias C Reichert; Stefano Romeo; Jerome I Rotter; Yu Ri Im; Nicola Santoro; Clemens Schafmayer; Elizabeth K Speliotes; Stefan Stender; Felix Stickel; Christopher D Still; Pavel Strnad; Kent D Taylor; Anne Tybjærg-Hansen; Giuseppina Rosaria Umano; Mrudula Utukuri; Luca Valenti; Lynne E Wagenknecht; Nicholas J Wareham; Richard M Watanabe; Julia Wattacheril; Hanieh Yaghootkar; Hannele Yki-Järvinen; Kendra A Young; Jake P Mann
Journal:  J Hepatol       Date:  2020-08-31       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.